# Handyem

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/handyem

- Industry: Medical Devices & Equipment
- Headquarters: Canada
- Website: www.handyem.com
- Total disclosed funding: $2.4M
- Latest round: Series B (Dec 4, 2014)
- Investors on record: 2

## About

Handyem is a Canadian company focused on developing advanced flow cytometry instruments, utilizing innovative optical fiber microfluidic technology to enhance research and clinical applications.Founded in 2010, Handyem specializes in creating cutting-edge flow cytometry instruments. The company has received CAD 2.75 mn in Series B funding on December 4, 2014, from Anges Quebec and Desjardins Capital. The headquarters is located in Canada, and the company has completed 2 funding deals to date. The founder's background details are not available.Handyem specializes in the development and production of advanced flow cytometry instruments, integrating optical fiber microfluidic technology with cytometry principles. Their offerings include compact, user-friendly devices for life science researchers, facilitating cell-based and bead-based assays. Applications include cell analysis, microbial analysis, immunology, and quality control within the biotech sector, serving a diverse client base across biomedical research, clinical diagnostics, and environmental science.Handyem generates revenue through the sale of flow cytometry instruments and proprietary AffiELISA® kits for biomarker detection. Their B2B transaction structure caters to research institutions and clinical laboratories, with a pricing strategy that accommodates various budgets while ensuring high-performance results. Key products include the AffiELISA® Mouse CD40 ELISA Kit and other specialized disease-specific kits, reflecting the company's focus on meeting client needs.Handyem plans to utilize the recent Series B funding of CAD 2.75 mn to support the design and launch of new products aimed at expanding their technological capabilities. They are targeting entry into new global markets, enhancing their reach in biomedical research and clinical diagnostics sectors by 2025. The funding will be instrumental in advancing their product development initiatives and expanding operational capacities.

## Funding rounds

- Series B, Dec 4, 2014, $2.4M — Desjardins Capital, Anges Quebec

## Investors

- Desjardins Capital (https://capitalatlas.ai/funds/desjardins-capital) — Series B
- Anges Quebec — Series B